search
Back to results

Mesenchymal Stromal Cells for Degenerative Meniscus Injury

Primary Purpose

Chronic Meniscal Injury

Status
Completed
Phase
Phase 1
Locations
Spain
Study Type
Interventional
Intervention
XCEL-M-ALPHA and standard rehabilitation
Rehabilitation
Sponsored by
Banc de Sang i Teixits
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Meniscal Injury focused on measuring Chronic Meniscal Injury, Degenerative meniscus, Meniscus injury, Meniscal injury, Mesenchymal stromal cells, Mesenchymal stem cells, Advanced Therapy, Bone marrow

Eligibility Criteria

40 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient between 40 and 60 years of age
  • Degenerative meniscus injury grade 3 (Crues et al.)
  • Indication of conservative treatment
  • Normal alignment of the knee (between 3º varus and 10 º valgus)
  • Patient is able to follow a rehabilitation program
  • Informed consent given by the patient in writing
  • Patient is able to understand the trial.

Exclusion Criteria:

  • Traumatic meniscus injury
  • Surgical intervention to the affected knee
  • Local or systemic infection
  • Intraarticular treatment of the affected knee with steroids or hyaluronic acid within the past 3 months
  • Significant abnormal laboratory tests that contraindicates participation in the trial.
  • Pregnant women or intend to become pregnant or breast-feeding
  • Neoplastic process within the previous 5 years or without complete remission.
  • The patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency or any other condition that contraindicates the magnetic resonance using contrast.
  • Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
  • Legally dependant patient.
  • The patient does not accept to be followed-up for a period that could exceed the clinical trial length

Sites / Locations

  • ICATME-Hospital Quiron Dexeus

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

XCEL-M-ALPHA and standard rehabilitation

standard rehabilitation

Arm Description

Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program

Standard rehabilitation program

Outcomes

Primary Outcome Measures

VAS for pain
Visual analogue scale (VAS) for pain at 12 month follow-up.

Secondary Outcome Measures

Safety
Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.
Efficacy by MRI
Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.
VAS for pain
Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.
Efficacy by clinical questionnaires
IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up

Full Information

First Posted
January 8, 2014
Last Updated
January 8, 2018
Sponsor
Banc de Sang i Teixits
Collaborators
Hospital Universitari Quirón Dexeus, Ministerio de Sanidad, Servicios Sociales e Igualdad
search

1. Study Identification

Unique Protocol Identification Number
NCT02033525
Brief Title
Mesenchymal Stromal Cells for Degenerative Meniscus Injury
Official Title
A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
January 31, 2014 (Actual)
Primary Completion Date
May 2, 2017 (Actual)
Study Completion Date
May 2, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Banc de Sang i Teixits
Collaborators
Hospital Universitari Quirón Dexeus, Ministerio de Sanidad, Servicios Sociales e Igualdad

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The present proposal has the objective to assess whether the addition of autologous ex vivo expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury rehabilitation program is contributing in creating the proper healing environment for the meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The conduction of this clinical trial will, in addition of having the aim of improving the patient's quality of life, contribute to consolidate an emerging new type of therapy which is still under development.
Detailed Description
This is a prospective, unicentric, randomized, open-label, single-dose, two-arm, blinded assessor pilot study in which 20 patients with degenerative meniscus injury grade 3 (Crues et al.) will enter the study with the primary objective of assessing the efficacy of the treatment by VAS of pain at 12 month. Secondary objectives are to evaluate the safety and efficacy through imaging procedures and clinical questionnaires (IKDC, KOOS, Lysholm and SF-36. Patients will be randomized to one of the two treatment arms (XCEL-M-ALPHA and standard rehabilitation program or standard rehabilitation program alone). Thereafter, patients will be followed for 12 months. Imaging assessment will be performed by an independent blinded radiologist.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Meniscal Injury
Keywords
Chronic Meniscal Injury, Degenerative meniscus, Meniscus injury, Meniscal injury, Mesenchymal stromal cells, Mesenchymal stem cells, Advanced Therapy, Bone marrow

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
XCEL-M-ALPHA and standard rehabilitation
Arm Type
Experimental
Arm Description
Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
Arm Title
standard rehabilitation
Arm Type
Active Comparator
Arm Description
Standard rehabilitation program
Intervention Type
Drug
Intervention Name(s)
XCEL-M-ALPHA and standard rehabilitation
Other Intervention Name(s)
XCEL-M-ALPHA
Intervention Description
Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
Intervention Type
Other
Intervention Name(s)
Rehabilitation
Intervention Description
Standard rehabilitation program
Primary Outcome Measure Information:
Title
VAS for pain
Description
Visual analogue scale (VAS) for pain at 12 month follow-up.
Time Frame
12 month
Secondary Outcome Measure Information:
Title
Safety
Description
Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.
Time Frame
12 month
Title
Efficacy by MRI
Description
Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.
Time Frame
6 and 12 month
Title
VAS for pain
Description
Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.
Time Frame
1, 3 and 6 month
Title
Efficacy by clinical questionnaires
Description
IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up
Time Frame
3, 6 and 12 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient between 40 and 60 years of age Degenerative meniscus injury grade 3 (Crues et al.) Indication of conservative treatment Normal alignment of the knee (between 3º varus and 10 º valgus) Patient is able to follow a rehabilitation program Informed consent given by the patient in writing Patient is able to understand the trial. Exclusion Criteria: Traumatic meniscus injury Surgical intervention to the affected knee Local or systemic infection Intraarticular treatment of the affected knee with steroids or hyaluronic acid within the past 3 months Significant abnormal laboratory tests that contraindicates participation in the trial. Pregnant women or intend to become pregnant or breast-feeding Neoplastic process within the previous 5 years or without complete remission. The patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency or any other condition that contraindicates the magnetic resonance using contrast. Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria Legally dependant patient. The patient does not accept to be followed-up for a period that could exceed the clinical trial length
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joan Carles Monllau, MD, PhD
Organizational Affiliation
ICATME-Hospital Quiron Dexeus
Official's Role
Principal Investigator
Facility Information:
Facility Name
ICATME-Hospital Quiron Dexeus
City
Barcelona
ZIP/Postal Code
08028
Country
Spain

12. IPD Sharing Statement

Links:
URL
http://www.bancsang.net/en/index.html
Description
Blood and tissue bank of Catalonia
URL
http://www.icatme.com/
Description
Fundación ICATME (Spanish only)

Learn more about this trial

Mesenchymal Stromal Cells for Degenerative Meniscus Injury

We'll reach out to this number within 24 hrs